Clinical Trial Results:
Open-label Pilot Study of Memantine in Chronic Cough Patients Attending a Specialist Clinic
Summary
|
|
EudraCT number |
2011-005151-13 |
Trial protocol |
GB |
Global end of trial date |
14 Aug 2013
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
11 Apr 2020
|
First version publication date |
11 Apr 2020
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
MEM-COUGH-01
|
||
Additional study identifiers
|
|||
ISRCTN number |
ISRCTN99941214 | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
REC reference: 11/NW/0840 | ||
Sponsors
|
|||
Sponsor organisation name |
Manchester University NHS Foundation Trust
|
||
Sponsor organisation address |
29 Grafton Street, Manchester, United Kingdom, M13 9WU
|
||
Public contact |
Dr. Jacky Smith, 11/NW/0840, +44 1612915879, jacky.smith@manchester.ac.uk
|
||
Scientific contact |
Dr. Jacky Smith, 11/NW/0840, +44 1612915879, jacky.smith@manchester.ac.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
14 Aug 2013
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
14 Aug 2013
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To evaluate the change in cough frequency in chronic cough patients after treatment with Memantine by assessing 24 hour cough frequency.
|
||
Protection of trial subjects |
All potential adverse effects and risks associated with taking part in the trial were fully explained to patients before they decided whether to participate.
It was made clear to patients at the beginning of the trial that although Memantine is a licensed medication it may not be possible for it to be prescribed for them "off-label" once the trial had ended and that treatment would be discontinued at the end of the study even if they had felt some benefit from taking it.
Objective cough monitoring involves patients wearing a digital recording device to capture how much they cough over a 24 hour period. The device records patient's conversations as well as cough sounds which could be heard by trained cough analysis staff. Any conversation recorded in this manner was treated in accordance with the GMC Confidentiality Booklet and the Data Protection Act. This was explained in detail to patients prior to their participation.
|
||
Background therapy |
No background therapy. | ||
Evidence for comparator |
This was an open-label study, no comparators were tested. | ||
Actual start date of recruitment |
17 Jan 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 14
|
||
Worldwide total number of subjects |
14
|
||
EEA total number of subjects |
14
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
8
|
||
From 65 to 84 years |
6
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
All patients were recruited from the specialist cough clinic held at University Hospital of South Manchester NHS Foundation Trust between February 2013 and August 2013. All patients were required to read the participant information sheet thoroughly prior to providing written consent. | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
17 patients were screened and 14 enrolled. Reasons for 3 screen failures were; uncontrolled hypertension, use of systemic anticholinergic and clinically significant abnormal blood result. Main criteria for inclusion were diagnosis of idiopathic chronic cough of >8 weeks duration, aged 18 years or over, normal chest x-ray and normal spirometry. | ||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
Baseline
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Not applicable
|
||||||||||||
Blinding used |
Not blinded | ||||||||||||
Arms
|
|||||||||||||
Arm title
|
Baseline | ||||||||||||
Arm description |
- | ||||||||||||
Arm type |
Enrolled | ||||||||||||
Investigational medicinal product name |
No treatment
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||
Routes of administration |
Unknown use
|
||||||||||||
Dosage and administration details |
N/A
|
||||||||||||
|
|||||||||||||
Period 2
|
|||||||||||||
Period 2 title |
Treatment Period
|
||||||||||||
Is this the baseline period? |
No | ||||||||||||
Allocation method |
Not applicable
|
||||||||||||
Blinding used |
Not blinded | ||||||||||||
Arms
|
|||||||||||||
Arm title
|
Memantine | ||||||||||||
Arm description |
Escalating doses of memantine 10-40mg | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
Memantine
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||
Routes of administration |
Oral use
|
||||||||||||
Dosage and administration details |
10-40mg OD doses escalating weekly if tolerated. Maximum tolerated dose continued for 4 weeks.
|
||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Baseline
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Baseline
|
||
Reporting group description |
- | ||
Reporting group title |
Memantine
|
||
Reporting group description |
Escalating doses of memantine 10-40mg |
|
|||||||||||||
End point title |
Awake cough frequency [1] | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
From baseline to end of treatment
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Details of the statistical analysis have not been inputted to the database as the fields are not tailored to this type of study. Two sided paired-sample t-tests were performed to compare post treatment measurements to baseline. There were no statistically significant differences with the p values for daytime cough frequency and total CQLQ score being p=0.141 and p=0.366 respectively. |
|||||||||||||
|
|||||||||||||
Notes [2] - 2 participants withdrew, 1 attended final visit with URTI so cough recording was not carried out [3] - 1 participant did not complete cough recording |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
CQLQ Score | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From baseline to end of treatment
|
||||||||||||
|
|||||||||||||
Notes [4] - 1 missing due to questionnaire being completed incorrectly [5] - 1 missing due to questionnaire being completed incorrectly |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From start of treatment to end of treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
16
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Memantine
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Single arm - escalating memantine treatment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
11 May 2012 |
Substantial Amendment 1.0: At the request of the MHRA, a section was added to the protocol (6.7) to describe and cover concomitant therapies. |
||
26 Nov 2012 |
Substantial Amendment 2.0: Changes were 1. The IMP brand was changed from Ebixa to Axura due to sourcing difficulties. 2. Alterations to eligibility wording around definition of child bearing potential and acceptable methods of contraception. 3. Altered eligibility criteria for uncontrolled hypertension with an increase in acceptable limit. 4. Altered wording to eligibility criteria with regards to history of seizures. 5. Altered wording for eligibility with regards to the use of tricyclic antidepressants. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |